GO:1900054 positive regulation of retinoic acid biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900054 describes any process that activates or increases the frequency, rate or extent of retinoic acid biosynthetic process [QuickGO definition].
• Retinoic acid (RA) biosynthesis requires sequential oxidation of retinol to retinaldehyde and then to all-trans-retinoic acid (ATRA), catalyzed by alcohol dehydrogenases (ADH) and retinaldehyde dehydrogenases (RALDH/ALDH1A) [3,5].
• Positive regulation of RA biosynthesis is essential for embryonic patterning, myelination, and tissue homeostasis [1,6].
• Dysregulated RA biosynthesis contributes to cancer, inflammation, and metabolic disorders, making it a therapeutic target [2,5,7].
• Key regulatory nodes include RALDH enzymes, CYP26 catabolic enzymes, and signaling inputs from progesterone receptors and MAF-related factors [5,7,8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of RA biosynthetic regulators in disease contexts [2,3,4].
Description
Retinoic acid (RA) is a vitamin A-derived morphogen that controls gene expression through retinoic acid receptors (RARs). The biosynthetic process converting retinol to all-trans-retinoic acid (ATRA) is tightly regulated, and GO:1900054 captures the positive regulation of this biosynthetic cascade. This term is critical for understanding how cells increase RA production in response to developmental or physiological cues [3,5]. RA biosynthesis occurs in two oxidative steps: retinol is first converted to retinaldehyde by alcohol dehydrogenases (ADHs), and retinaldehyde is then irreversibly oxidized to ATRA by retinaldehyde dehydrogenases (RALDH1/2/3, encoded by ALDH1A1/2/3) [3,5]. Positive regulation of this process can occur at transcriptional, post-transcriptional, or metabolic levels, often through increased expression or activity of RALDH enzymes [3,7]. Researchers study GO:1900054 to understand embryonic patterning, myelination, immune regulation, and cancer differentiation. For example, RA release from NG2-positive cells regulates myelination, and RA signaling gradients pattern the mesoderm. Dysregulation of RA biosynthesis is implicated in synovial sarcoma, breast cancer, and adipose tissue dysfunction [2,3,7]. This article provides a research-grade overview of the genes, mechanisms, and CRISPR methods used to study positive regulation of retinoic acid biosynthetic process.
positive regulation of retinoic acid biosynthetic process At A Glance
| GO ID | GO:1900054 |
|---|---|
| GO term | positive regulation of retinoic acid biosynthetic process |
| Ontology | biological_process |
| Synonym | activation of retinoic acid biosynthetic process; upregulation of retinoic acid biosynthetic process; positive regulation of retinoic acid anabolic process |
| Major function | Upregulation of the enzymatic conversion of retinol to all-trans-retinoic acid (ATRA) |
| Key enzymes | RALDH1/2/3 (ALDH1A1/2/3), ADH family, CYP26 family (catabolic) |
| Related processes | Retinol metabolism, embryonic patterning, myelination, immune regulation |
| Disease relevance | Cancer, inflammation, metabolic disorders, synovial sarcoma |
What Is GO:1900054?
GO:1900054 (positive regulation of retinoic acid biosynthetic process) is a biological process ontology term defined as any process that activates or increases the frequency, rate or extent of retinoic acid biosynthetic process. In other words, it encompasses molecular events that upregulate the production of retinoic acid from its precursors, including increased expression or activity of biosynthetic enzymes, reduced catabolism, or enhanced substrate availability [QuickGO definition].
Why Is positive regulation of retinoic acid biosynthetic process Important in Cell Biology?
Positive regulation of retinoic acid biosynthesis is essential for development and tissue homeostasis. RA acts as a diffusible morphogen that patterns the embryo, and its local concentration must be precisely controlled. In adults, RA regulates myelination, immune function, and epithelial differentiation [1,7]. Dysregulation of RA biosynthesis is linked to cancer progression, inflammatory diseases, and metabolic dysfunction [2,5]. Understanding GO:1900054 provides mechanistic insight into how cells modulate RA production and offers therapeutic opportunities for modulating RA signaling.
• Controls embryonic patterning and organogenesis through dynamic RA gradients.
• Regulates myelination via exosome-associated RA release from NG2-positive cells.
• Modulates immune responses and inflammation through RA-metabolizing enzymes.
• Influences cancer cell differentiation and senescence, as seen in synovial sarcoma.
• Affects adipose tissue function via depot-specific RA biosynthesis.
• Cross-talks with progesterone receptor signaling in breast cancer cells.
• Regulates vascular endothelial growth factor (VEGF) in amnion.
• Provides targets for therapeutic intervention in differentiation therapy [2,5].
• Serves as a model for studying morphogen gradient formation.
• Enables CRISPR-based dissection of gene regulatory networks [2,3,4].
What Happens During positive regulation of retinoic acid biosynthetic process?
Retinol Uptake and First Oxidation
In simple terms: The cell takes up vitamin A and converts it to an intermediate.
Positive regulation begins with increased retinol uptake or enhanced activity of alcohol dehydrogenases (ADHs) that oxidize retinol to retinaldehyde. This step is rate-limiting under certain conditions and can be upregulated by transcriptional induction of ADH genes or by increased substrate availability [3,5].
Second Oxidation by RALDH Enzymes
In simple terms: The intermediate is converted into active retinoic acid by RALDH enzymes.
Retinaldehyde is irreversibly oxidized to all-trans-retinoic acid (ATRA) by retinaldehyde dehydrogenases (RALDH1, RALDH2, RALDH3, encoded by ALDH1A1, ALDH1A2, ALDH1A3). Positive regulation of RA biosynthesis often involves increased expression or activity of these enzymes. For example, RALDH2 is dynamically expressed during mesoderm patterning, and RALDH1 is regulated in adipose tissue.
Transcriptional Control of Biosynthetic Genes
In simple terms: Genes that make RA are turned on by specific transcription factors.
Transcriptional upregulation of ALDH1A genes is a key mechanism for positive regulation. MAF-related factors directly regulate vHnf1 in the neural tube, linking RA signaling to developmental gene networks. Progesterone receptors cross-talk with retinoic acid receptors to modulate cytokeratin 5 in breast cancer cells, indirectly affecting RA biosynthesis.
Inhibition of RA Catabolism
In simple terms: Blocking the enzymes that destroy RA increases its levels.
CYP26 enzymes (CYP26A1, CYP26B1, CYP26C1) catabolize ATRA. Positive regulation of RA biosynthesis can be achieved by downregulating CYP26 expression or activity, thereby prolonging RA half-life. This mechanism is relevant in inflammation and cancer, where CYP26 inhibitors are being explored.
Exosome-Mediated RA Release
In simple terms: Cells can package RA into vesicles to deliver it to other cells.
NG2-positive cells release exosomes containing RA, which regulates myelination. This represents a non-cell-autonomous mechanism for positive regulation of RA availability in target tissues.
Key Genes Involved in GO:1900054 positive regulation of retinoic acid biosynthetic process
The following genes and proteins are central to the positive regulation of retinoic acid biosynthetic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALDH1A1 (RALDH1) | Oxidizes retinaldehyde to ATRA | Adipose tissue RA biosynthesis; cancer differentiation [3,5] |
| ALDH1A2 (RALDH2) | Major embryonic RA-producing enzyme | Mesoderm patterning; neural tube development [6,8] |
| ALDH1A3 (RALDH3) | RA synthesis in specific tissues | Cancer stem cells; synovial sarcoma [2,5] |
| ADH1 | Oxidizes retinol to retinaldehyde | First step of RA biosynthesis [3,5] |
| ADH4 | Retinol oxidation in epidermis | Skin differentiation; cancer |
| CYP26A1 | Catabolizes ATRA | Negative regulator; target for increasing RA |
| CYP26B1 | Catabolizes ATRA | Inflammation and cancer |
| CYP26C1 | Catabolizes ATRA | Embryonic development |
| RARα | Mediates RA signaling | Breast cancer; differentiation |
| RARβ | Mediates RA signaling | Tumor suppression |
| RXRα | Heterodimer partner for RAR | RA signaling |
| MAF | Transcription factor regulating RA-related genes | Neural tube development |
| vHnf1 | Target of RA signaling | Neural tube patterning |
| EZH2 | Epigenetic regulator | Synovial sarcoma; RA-driven senescence |
| VEGF | Angiogenic factor regulated by RA | Amnion biology |
| NG2 (CSPG4) | Proteoglycan on NG2-positive cells | Exosome-mediated RA release; myelination |
| Progesterone receptor | Cross-talks with RAR | Breast cancer |
How Is positive regulation of retinoic acid biosynthetic process Regulated?
Positive regulation of retinoic acid biosynthesis is controlled at multiple levels. Transcriptional regulation of ALDH1A genes by developmental cues and transcription factors such as MAF-related factors directly impacts RA production. Post-transcriptional mechanisms, including mRNA stability and microRNAs, can modulate RALDH levels. Metabolic regulation involves substrate availability (retinol) and competition with catabolic enzymes (CYP26). Signaling pathways such as progesterone receptor signaling cross-talk with retinoic acid receptors to influence RA-responsive genes. Additionally, exosome-mediated release of RA from NG2-positive cells provides a non-cell-autonomous regulatory mechanism. EZH2 inhibition can sensitize cells to RA-driven senescence, linking epigenetic regulation to RA biosynthesis.
positive regulation of retinoic acid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALDH1A2 | Neural tube defects; mesoderm patterning | Knockout mouse; zebrafish; CRISPR KO in stem cells [6,8] |
| CYP26A1 | Cancer; inflammation | Overexpression and KO cell lines; xenograft models |
| EZH2 | Synovial sarcoma | CRISPR KO; point mutation; drug combination |
| RARα | Breast cancer | Knock-in reporter; overexpression |
| ALDH1A1 | Adipose tissue dysfunction; obesity | Depot-specific KO; overexpression |
Cancer
Dysregulated RA biosynthesis is implicated in multiple cancers. In synovial sarcoma, EZH2 inhibition sensitizes cells to retinoic acid-driven senescence, suggesting that modulating RA biosynthesis could be therapeutic. In breast cancer, cross-talk between progesterone receptors and retinoic acid receptors regulates cytokeratin 5-positive cells, affecting tumor differentiation. CYP26 enzymes, which catabolize RA, are often overexpressed in cancers, reducing RA availability and promoting tumor growth.
Inflammation and Immune Regulation
RA plays a critical role in immune cell differentiation and function. CYP26 enzymes are induced by inflammatory cytokines, leading to increased RA catabolism and reduced RA signaling. Positive regulation of RA biosynthesis can therefore be anti-inflammatory. Targeting CYP26 or enhancing RALDH activity is being explored in inflammatory diseases.
Metabolic and Adipose Tissue Disorders
RA biosynthesis is depot-specific in human adipose tissue, with implications for metabolic health. Rubinow et al. demonstrated that all-trans-retinoic acid biosynthesis is regulated differently in subcutaneous versus visceral fat, affecting adipocyte function and insulin sensitivity.
Developmental Disorders
Proper RA gradients are essential for embryonic patterning. Disruption of RA biosynthesis leads to neural tube defects, limb malformations, and organogenesis defects. Mesoderm patterning by dynamic RA gradients is a paradigm for morphogen action, and vHnf1 regulation by RA signaling and MAF-related factors is critical in the neural tube.
From positive regulation of retinoic acid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ALDH1A2 reduce RA biosynthesis? | CRISPR knockout of ALDH1A2 in cell lines or organoids |
| Does a point mutation in RALDH2 alter enzyme activity? | CRISPR point mutation knock-in of catalytic residue |
| Does overexpression of RALDH1 increase RA levels? | CRISPR knock-in of inducible promoter or cDNA overexpression |
| How does CYP26A1 catabolism affect RA gradients? | CRISPR knockout or overexpression of CYP26A1 |
| Can EZH2 inhibition enhance RA-driven senescence? | CRISPR knockout of EZH2 combined with RA treatment |
| What is the role of exosomal RA release? | CRISPR knockout of NG2 in NG2-positive cells |
How to Study the positive regulation of retinoic acid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Expression of RA biosynthetic and catabolic genes | Identify transcriptional upregulation [3,7] |
| LC-MS/MS | Retinol, retinaldehyde, ATRA levels | Quantify RA biosynthesis |
| RARE-luciferase reporter | RA signaling activity | Screen for regulators |
| CRISPR knockout screen | Genes required for RA biosynthesis | Identify positive regulators [2,5] |
| CRISPR activation screen | Genes that increase RA biosynthesis | Discover enhancers |
| Immunohistochemistry | RALDH enzyme localization | Tissue-specific RA production [1,6] |
| Exosome isolation | Exosome-associated RA | Non-cell-autonomous RA release |
| ChIP-seq | Transcription factor binding to ALDH1A promoters | Identify direct regulators |
Transcriptional Profiling (RNA-seq)
RNA sequencing can quantify expression of RA biosynthetic genes (ALDH1A1/2/3, ADH) and catabolic genes (CYP26) under conditions that positively regulate RA biosynthesis. This method identifies transcriptional changes driving increased RA production [3,7].
Metabolite Quantification (LC-MS/MS)
Liquid chromatography-tandem mass spectrometry measures retinol, retinaldehyde, and ATRA levels directly, providing a quantitative readout of RA biosynthesis. This is the gold standard for validating positive regulation.
Reporter Assays (RARE-luciferase)
Retinoic acid response element (RARE)-driven luciferase reporters measure RA signaling activity indirectly. Increased reporter activity indicates enhanced RA biosynthesis or signaling.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify positive regulators of RA biosynthesis by selecting for cells with altered RA levels or RA-dependent phenotypes [2,5].
How CRISPR Can Be Used to Study GO:1900054 positive regulation of retinoic acid biosynthetic process
Knockout
CRISPR knockout of ALDH1A genes or CYP26 genes can abolish or enhance RA biosynthesis, respectively. For example, ALDH1A2 knockout reduces RA production, while CYP26A1 knockout increases RA levels. These models are used to study developmental defects and cancer differentiation [2,5,6].
Point Mutation
CRISPR point mutation can introduce catalytic-dead mutations in RALDH enzymes to dissect enzymatic versus non-enzymatic functions. For instance, mutating the catalytic cysteine of ALDH1A2 abolishes RA synthesis, allowing separation of RA-dependent and independent roles.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into ALDH1A2 or CYP26A1 loci enables real-time tracking of enzyme expression and localization. Knock-in of inducible promoters allows controlled overexpression of RA biosynthetic enzymes [3,6].
Overexpression
CRISPR-mediated overexpression of RALDH1 or RALDH2 using a safe-harbor locus or inducible system increases RA production, useful for studying the consequences of enhanced RA biosynthesis in cancer and differentiation [2,7].
How EDITGENE Supports positive regulation of retinoic acid biosynthetic process Research
Researchers studying positive regulation of retinoic acid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in RA production or merely correlated. EDITGENE provides a comprehensive suite of CRISPR services to enable such causal studies, from knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of retinoic acid biosynthetic process research.
Frequently Asked Questions About positive regulation of retinoic acid biosynthetic process
What is GO:1900054?
GO:1900054 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of retinoic acid biosynthetic process [QuickGO definition].
What genes are involved in positive regulation of retinoic acid biosynthetic process?
Key genes include ALDH1A1, ALDH1A2, ALDH1A3 (RALDH enzymes), ADH family members, CYP26 catabolic enzymes, and transcription factors such as MAF and vHnf1 [3,5,6,8].
How is retinoic acid biosynthesis regulated?
It is regulated at transcriptional, post-transcriptional, and metabolic levels, including expression of RALDH enzymes, inhibition of CYP26 catabolism, and exosome-mediated release [1,3,5].
What diseases are associated with dysregulated retinoic acid biosynthesis?
Cancer (e.g., synovial sarcoma, breast cancer), inflammation, metabolic disorders, and developmental defects [2,5,7].
What is the role of RALDH2 in RA biosynthesis?
RALDH2 (ALDH1A2) catalyzes the irreversible oxidation of retinaldehyde to ATRA and is critical for embryonic patterning and neural tube development [6,8].
How can CRISPR be used to study positive regulation of RA biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models can dissect the causal roles of specific genes in RA production [2,3,5].
What methods measure retinoic acid levels?
LC-MS/MS is the gold standard for quantifying retinol, retinaldehyde, and ATRA. RARE-luciferase reporters measure RA signaling activity [3,6].
What is the connection between CYP26 and RA biosynthesis?
CYP26 enzymes catabolize ATRA; inhibiting CYP26 increases RA availability, effectively positively regulating RA biosynthesis.
How does EZH2 affect retinoic acid-driven senescence?
EZH2 inhibition sensitizes synovial sarcoma cells to retinoic acid-driven senescence, linking epigenetic regulation to RA sensitivity.
What cell models are available for studying RA biosynthesis?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for genes such as ALDH1A2, CYP26A1, and EZH2 [2,3,5].
Conclusion
GO:1900054 (positive regulation of retinoic acid biosynthetic process) is a critical biological process that controls the production of retinoic acid, a key morphogen and signaling molecule. Understanding its regulation provides insights into development, cancer, inflammation, and metabolism. The genes and mechanisms described here, supported by published literature, offer a foundation for further research. CRISPR-based models from EDITGENE enable precise causal studies to advance this field.
References
- 1. Goncalves MB et al.. 2019. Regulation of Myelination by Exosome Associated Retinoic Acid Release from NG2-Positive Cells.. J Neurosci 39(16):3013-3027 PMID: 30760627
- 2. Mushtaq M et al.. 2024. EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma.. Cell Death Dis 15(11):836 PMID: 39550391
- 3. Rubinow KB et al.. 2022. Evidence of depot-specific regulation of all-trans-retinoic acid biosynthesis in human adipose tissue.. Clin Transl Sci 15(6):1460-1471 PMID: 35213790
- 4. Cheung CY et al.. 2019. Retinoic Acid Pathway Regulation of Vascular Endothelial Growth Factor in Ovine Amnion.. Reprod Sci 26(10):1351-1359 PMID: 29587617
- 5. Stevison F et al.. 2015. Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.. Adv Pharmacol 74:373-412 PMID: 26233912
- 6. Bernheim S et al.. 2020. Mesoderm patterning by a dynamic gradient of retinoic acid signalling.. Philos Trans R Soc Lond B Biol Sci 375(1809):20190556 PMID: 32829679
- 7. Fettig LM et al.. 2017. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.. Oncogene 36(44):6074-6084 PMID: 28692043
- 8. Pouilhe M et al.. 2007. Direct regulation of vHnf1 by retinoic acid signaling and MAF-related factors in the neural tube.. Dev Biol 309(2):344-57 PMID: 17669392
